Probe into GSK's Paxil expands
Pharma Compliance Alert, June 25, 2008
More questions are being raised about GlaxoSmithKline’s (GSK) antidepressant Paxil, according to a Philadelphia Inquirer article.
On June 12, Senator Charles Grassley (R-IA) sent a letter to the FDA asking the agency to determine whether GSK withheld information about the suicide risks associated with Paxil.
On Thursday, GSK confirmed it is also being investigated by Justice Department offices in Colorado, Boston, and Washington for its alleged off-label marketing practices for Paxil.
In 2007, GSK paid $64 million to settle a class action lawsuit claiming it misled consumers about Paxil’s safety. In settling the suit, GSK denied claims it promoted Paxil for use in children while withholding information about serious negative side effects.
Comments
0 comments on “Probe into GSK's Paxil expands ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Case Management Monthly, June 2012
- Searched